Pharma Stock Cracks $10 Billion Rare Disease Market; Rs 250 Cr Revenue Trigger Ahead

With the successful development of a novel combination of Active Pharmaceutical Ingredients (APIs) for cystic fibrosis (CF) that includes Vanzacaftor, Tezacaftor, and Deutivacaftor, Sigachi Industries Ltd., a prominent pharmaceutical company in India, announced today a major milestone in its research and development pipeline.

In line with the global need for cutting-edge treatments in the rare and chronic disease segments, the development represents a significant step in Sigachi's strategic emphasis on growing its footprint in complex, high-value specialized APIs.

The growing popularity of next-generation modulator therapies, long-term treatment needs, and robust pricing resiliency are driving the anticipated USD 10 billion global market for cystic fibrosis medications. In light of this, Sigachi's move into CF APIs places the company in a therapeutic market with long-term demand visibility that is both innovative and structurally sound.

The company is currently investigating strategic partnerships with formulation inventors for R&D and eventual commercial supply of these CF APIs, based on internal market assessment and strategic evaluation. The company projects a revenue potential of over Rs 250 crore annually starting in Q4 FY2026-2027, subject to successful collaborations and market advancement, making this portfolio a significant growth driver.

Lijo Chacko, Deputy Group CEO, Sigachi Industries Limited, said, "This milestone reflects Sigachi's focused strategy of building depth in complex and differentiated APIs with long-term growth visibility. Our continued investments in R&D and partnerships are aimed at strengthening our position in high-entry-barrier specialty segments and creating sustainable value for stakeholders."

Advanced chemistry, multi-step synthesis, and specialized reactions are all part of the CF API package, which reduces the level of competition and strengthens Sigachi's capabilities in sophisticated API manufacture by creating high technological complexity and substantial obstacles to entry. Vanzacaftor's innovator patent protection, which lasts until 2039, further enhances long-term visibility and offers steady revenue stability and collaboration-led commercial opportunities in the cystic fibrosis therapeutic market.

While cautiously expanding innovative, high-value prospects in line with its long-term growth plan, Sigachi Industries is still concentrating on fortifying its core businesses. Active pharmaceutical ingredients (APIs), intermediates, excipients, vitamin-mineral blends, and operations and management (O&M) services are all areas of innovation for Sigachi Industries Limited, a major player in the pharmaceutical business on a global scale. Telangana, Gujarat, and Karnataka are the five multilocation facilities where the corporation produces its wide range of products.

Sigachi is a reliable partner for pharmaceutical and nutraceutical firms operating in more than 65 countries, with 36 years of expertise in the field.